Alessandra Tedeschi

Summary

Affiliation: Niguarda Hospital
Country: Italy

Publications

  1. doi request reprint Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia
    Alessandra Tedeschi
    Division of Hematology, Ospedale Niguarda Ca Granda Milano, Milano, Italy
    Clin Lymphoma Myeloma Leuk 13:231-4. 2013
  2. ncbi request reprint Cryoglobulinemia
    Alessandra Tedeschi
    Department Oncology Haematology, Division of Haematology, Nigurda Ca Granda Hospital Milano, Italy
    Blood Rev 21:183-200. 2007
  3. doi request reprint Fludarabine-based combination therapies for Waldenström's macroglobulinemia
    Alessandra Tedeschi
    Department of Hematology, Niguarda Ca Granda Hospital, Milano, Italy
    Clin Lymphoma Myeloma 9:67-70. 2009
  4. doi request reprint Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease
    Alessandra Tedeschi
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 118:434-43. 2012
  5. doi request reprint Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia
    Marco Montillo
    Department of Oncology Hematology, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore 3, Milano, Italy
    Leuk Res 33:1072-8. 2009
  6. doi request reprint Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
    Alessandra Trojani
    Department of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Clin Lymphoma Myeloma Leuk 13:208-10. 2013
  7. doi request reprint Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia?
    Francesca Ricci
    Department of Oncology Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Clin Lymphoma Myeloma Leuk 13:441-6. 2013
  8. doi request reprint Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia
    Alessandra Trojani
    Department of Oncology, Division of Hematology, Niguarda Hospital, Milan, Italy
    Cancer Biomark 11:15-28. 2011
  9. doi request reprint ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia
    Alessandra Trojani
    Niguarda Ca Granda Hospital, Division of Hematology, Milan, Italy
    Cancer Biomark 6:1-9. 2010
  10. doi request reprint Factors predicting transformation of asymptomatic IgM monoclonal gammopathy
    Antonino Greco
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Clin Lymphoma Myeloma Leuk 11:77-9. 2011

Collaborators

Detail Information

Publications32

  1. doi request reprint Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia
    Alessandra Tedeschi
    Division of Hematology, Ospedale Niguarda Ca Granda Milano, Milano, Italy
    Clin Lymphoma Myeloma Leuk 13:231-4. 2013
    ..The results of this study suggest that the FCR regimen might overcome poor prognostic features and should be taken into account as salvage treatment. Tardive immunosuppression and myelosuppression warrant accurate patient follow-up...
  2. ncbi request reprint Cryoglobulinemia
    Alessandra Tedeschi
    Department Oncology Haematology, Division of Haematology, Nigurda Ca Granda Hospital Milano, Italy
    Blood Rev 21:183-200. 2007
    ..Antiviral therapy may also be effective in determining the regression of B-cell lymphoproliferative disorder. Rituximab could represent a safe and effective alternative to standard immunosuppression and exerts selective B-cell control...
  3. doi request reprint Fludarabine-based combination therapies for Waldenström's macroglobulinemia
    Alessandra Tedeschi
    Department of Hematology, Niguarda Ca Granda Hospital, Milano, Italy
    Clin Lymphoma Myeloma 9:67-70. 2009
    ....
  4. doi request reprint Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease
    Alessandra Tedeschi
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 118:434-43. 2012
    ..The authors report the final results from a multicenter, prospective study examining FCR in Waldenstrom macroglobulinemia (WM)...
  5. doi request reprint Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia
    Marco Montillo
    Department of Oncology Hematology, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore 3, Milano, Italy
    Leuk Res 33:1072-8. 2009
    ..This schedule resulted effective and tolerable enabling 53% of the responding patients to receive transplant procedure. FLAIRG regimen could be proposed as a "bridge" to transplant treatment in this poor risk setting...
  6. doi request reprint Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
    Alessandra Trojani
    Department of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Clin Lymphoma Myeloma Leuk 13:208-10. 2013
    ....
  7. doi request reprint Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia?
    Francesca Ricci
    Department of Oncology Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Clin Lymphoma Myeloma Leuk 13:441-6. 2013
    ..The aim of this retrospective study was to investigate the relationship between the occurrence of a positive DAT and biological features of CLL patients...
  8. doi request reprint Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia
    Alessandra Trojani
    Department of Oncology, Division of Hematology, Niguarda Hospital, Milan, Italy
    Cancer Biomark 11:15-28. 2011
    ....
  9. doi request reprint ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia
    Alessandra Trojani
    Niguarda Ca Granda Hospital, Division of Hematology, Milan, Italy
    Cancer Biomark 6:1-9. 2010
    ....
  10. doi request reprint Factors predicting transformation of asymptomatic IgM monoclonal gammopathy
    Antonino Greco
    Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Clin Lymphoma Myeloma Leuk 11:77-9. 2011
    ..Among patients with aIgM-MG, those at high risk of evolution were patients with sWM, a distinct entity with serum IgM monoclonal protein≥3 g/dL and/or ≥10% bone marrow lymphoplasmacytic infiltration...
  11. ncbi request reprint High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study
    Alessandra Tedeschi
    Department of Oncology Hematology, Division of Hematology, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore, 3, 20162, Milan, and Department of Organic Chemistry, University of Bologna, Italy
    Cancer Chemother Pharmacol 59:771-9. 2007
    ....
  12. doi request reprint An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Marco Montillo
    Department of Oncology Haematology, Niguarda Ca Granda Hospital, Milano, Italy
    Blood 118:4079-85. 2011
    ..However, close vigilance of opportunistic infections is warranted. FCC provides effective immunotherapy in relapsed/refractory CLL, including in patients with poor-risk prognostic factors...
  13. doi request reprint Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition
    Enrica Morra
    Division of Hematology, Niguarda Ca Granda Hospital, Milano, Italy
    Clin Lymphoma Myeloma Leuk 13:700-3. 2013
    ..The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear...
  14. doi request reprint Bendamustine: new perspective for an old drug in lymphoproliferative disorders
    Marco Montillo
    Department of Oncology Haematology, Division of Haematology, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore 3, Milan, Italy
    Expert Rev Hematol 3:131-48. 2010
    ..Furthermore, its documented favorable toxicity profile makes it a particularly useful treatment option for elderly patients...
  15. doi request reprint Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature
    Laura Marbello
    Department of Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Leuk Res 32:1221-7. 2008
    ..In most of the reviewed series hyperleukocytosis does not seem to influence the outcome of patients. Avoiding early death seems to be an important step in this subset of patients. New data about pathophysiology of leukostasis are needed...
  16. ncbi request reprint Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
    Marco Montillo
    Department of Hematology, Laboratory of Flow Cytometry, Transfusion Medicine Service, Niguarda Ca Granda Hospital, Milano, Milan, Italy
    J Clin Oncol 24:2337-42. 2006
    ..Subsequent peripheral blood stem-cell (PBSC) collection and transplantation, tolerability, and pharmacokinetics also were assessed...
  17. ncbi request reprint Role of fludarabine in hematological malignancies
    Marco Montillo
    Department of Oncology Haematology, Division of Haematology, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    Expert Rev Anticancer Ther 6:1141-61. 2006
    ..Other strategies have incorporated fludarabine into preparative regimens for nonmyeloablative stem-cell transplantation...
  18. pmc Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Marco Montillo
    Department of Oncology Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca Granda Hospital, Milan, Italy
    Biologics 2:41-52. 2008
    ..Future areas of research will include the use of alemtuzumab in combination with other monoclonal antibodies and other targeted therapies...
  19. pmc The spectrum of use of rituximab in chronic lymphocytic leukemia
    Alessandra Tedeschi
    Department of Hematology, Niguarda Ca Granda Hospital, Milano, Italy
    Onco Targets Ther 3:227-46. 2010
    ..This review brings together knowledge of the pharmacokinetics, mechanism of action and clinical use of rituximab in chronic lymphocytic leukemia...
  20. ncbi request reprint Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
    Marco Montillo
    Department of Oncology Haematology, Division of Haematology, Niguarda Ca Granda Hospital, Piazza dell Ospedale Maggiore 3, 20161 Milan, Italy
    Cancer 97:114-20. 2003
    ..To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL)...
  21. doi request reprint Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation
    Andrea Ferrario
    Hematology Unit 1, IRCCS Foundation, Ca Granda Hospital Maggiore Policlinico, University of Milan, Milan, Italy
    Cancer 118:3954-61. 2012
    ..Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell proliferations for which treatment has not been defined to date...
  22. pmc Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia
    Francesca Ricci
    Division of Hematology, Niguarda Ca Granda Hospital, Milano, Italy
    Mediterr J Hematol Infect Dis 3:e2011031. 2011
    ..In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed...
  23. pmc Fludarabine in the treatment of chronic lymphocytic leukemia: a review
    Francesca Ricci
    Department of Oncology Haematology, Niguarda Ca Granda Hospital, Milan, Italy
    Ther Clin Risk Manag 5:187-207. 2009
    ..The current paper provides an overview of use of FAMP as a single agent or as a cornerstone of different therapeutic strategies for treatment of B-CLL patients...
  24. ncbi request reprint Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients
    Luisa Doneda
    Department of Biology and Genetics Medical Faculty, University of Milan, Milan, Italy
    Cancer Genet Cytogenet 140:31-6. 2003
    ..In contrast, monoallelic TP53 deletions were found in all of the patients. The TP53 and 11q deletions were only present in a proportion of the clonal B-cells, which suggests that they are secondary events in B-CLL...
  25. doi request reprint 'Use it again!': retherapy with bendamustine in indolent B-cell lymphoproliferative disorders
    Marco Montillo
    Department of Haematology and Oncology, Niguarda Ca Granda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    Expert Rev Hematol 6:247-50. 2013
    ....
  26. ncbi request reprint The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial
    Giuseppe Cimino
    Division of Hematology, Dept of Cellular Biotechnology and Hematology, University La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Haematologica 91:377-80. 2006
    ..By contrast, the p190 emerged as the only independent prognostic factor favorably affecting the 5-year overall survival and disease-free survival rates (p=0.008 and p=0.02, respectively)...
  27. ncbi request reprint Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia
    Stefano Molica
    Department of Hematology Oncology, A O Pugliese Ciaccio, Viale Pio X, 88100 Catanzaro, Italy
    Haematologica 92:1367-74. 2007
    ..The anti-angiogenic potential of alemtuzumab in CLL has not yet been investigated. We, therefore, evaluated BM angiogenesis in CLL patients treated sequentially with fludarabine and low doses of alemtuzumab...
  28. ncbi request reprint Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine
    Marco Montillo
    Divisione di Ematologia, Dipartmento di Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    Haematologica 87:695-700; discussion 700. 2002
    ..Granulocyte colony-stimulating factor (G-CSF), at the dosage of 5-10 microg/kg/die, or intermediate-dose Ara-C (800 mg/m(2)/q 12h x 6 doses), was administered to obtain peripheral blood stem cell (PBSC) mobilization...
  29. ncbi request reprint A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol
    Marco Mancini
    Department of Cellular Biotechnologies and Hematology, University La Sapienza Via Benevento 6 Rome, 00161 Italy
    Blood 105:3434-41. 2005
    ....
  30. ncbi request reprint High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation
    Roberto Cairoli
    Haematologica 89:361-3. 2004
    ..Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft...
  31. ncbi request reprint MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
    Agostino Tafuri
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Roma, Italy
    Blood 100:974-81. 2002
    ..MDR1 expression did not correlate with CR duration, nor did it predict for survival duration. These results demonstrate that MDR1 expression in de novo adult ALL is an independent predictor of CR achievement...
  32. ncbi request reprint The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease
    Francesco DiRaimondo
    Institute of Hematology, University of Catania, Italy
    Cancer 94:1721-30. 2002
    ..CD23 antigen is a cell surface protein considered important in the differentiation of chronic lymphocytic leukemia (CLL) from other lymphoid leukemias...